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Abstract
Recombinant adeno-associated viral (rAAV) vectors can be used to introduce neurotrophic genes into injured CNS neurons,
promoting survival and axonal regeneration. Gene therapy holds much promise for the treatment of neurotrauma and
neurodegenerative diseases; however, neurotrophic factors are known to alter dendritic architecture, and thus we set out to
determine whether such transgenes also change the morphology of transduced neurons. We compared changes in
dendritic morphology of regenerating adult rat retinal ganglion cells (RGCs) after long-term transduction with rAAV2
encoding: (i) green fluorescent protein (GFP), or (ii) bi-cistronic vectors encoding GFP and ciliary neurotrophic factor (CNTF),
brain-derived neurotrophic factor (BDNF) or growth-associated protein-43 (GAP43). To enhance regeneration, rats received
an autologous peripheral nerve graft onto the cut optic nerve of each rAAV2 injected eye. After 5–8 months, RGCs with
regenerated axons were retrogradely labeled with fluorogold (FG). Live retinal wholemounts were prepared and GFP
positive (transduced) or GFP negative (non-transduced) RGCs injected iontophoretically with 2% lucifer yellow. Dendritic
morphology was analyzed using Neurolucida software. Significant changes in dendritic architecture were found, in both
transduced and non-transduced populations. Multivariate analysis revealed that transgenic BDNF increased dendritic field
area whereas GAP43 increased dendritic complexity. CNTF decreased complexity but only in a subset of RGCs. Sholl analysis
showed changes in dendritic branching in rAAV2-BDNF-GFP and rAAV2-CNTF-GFP groups and the proportion of FG positive
RGCs with aberrant morphology tripled in these groups compared to controls. RGCs in all transgene groups displayed
abnormal stratification. Thus in addition to promoting cell survival and axonal regeneration, vector-mediated expression of
neurotrophic factors has measurable, gene-specific effects on the morphology of injured adult neurons. Such changes will
likely alter the functional properties of neurons and may need to be considered when designing vector-based protocols for
the treatment of neurotrauma and neurodegeneration.
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Introduction
Replication-deficient viral vectors such as recombinant adeno-
associated virus (rAAV) are increasingly being used to introduce
‘therapeutic’ genes into neural cells, a method that allows targeted
supply of neuroprotective and/or growth-promoting molecules to
the injured or degenerating CNS [1–5]. In the eye, vitreal injection
of rAAV serotype 2 (rAAV2) or other viral vectors encoding growth
factors increases retinal ganglion cell (RGC) survival and axonal
regeneration after optic nerve (ON) injury [6–9].
The gene therapy approach holds much promise for the
treatment of neurodegenerative diseases and retinal dystrophies
[10–13], as well as potentially enhancing repair after neurotrauma
[14]. However, what is not yet clear is the extent to which long-
term constitutive expression of transgenes changes the structure
and function of transduced neurons. This is especially relevant
when using genes that encode, for example, secretable neuro-
trophic factors because these peptides are known to alter dendritic
architecture, synaptic density and plasticity, cause down-regulation
of cognate receptors and modulate activity of signaling molecules
[15–19]. Thus persistent over-expression of some transgenes may
alter local circuitry and neuronal responsiveness to endogenous
neuroactive factors [1,20,21].
We therefore set out to determine whether soma size and
dendritic architecture is altered after prolonged rAAV2 vector
transduction, and whether any such changes depend on the type of
gene that is introduced into CNS neurons. Because rAAV based
gene therapy will potentially be used in post-injury as well as
neurodegenerative conditions, we chose to use our established
visual system regeneration model to quantitatively analyze changes
in adult rat RGCs that had been axotomized and then induced to
regenerate. RGC viability and long-distance axonal regeneration
was promoted by grafting an autologous peripheral nerve (PN)
segment onto the cut ON [22,23]. Four vectors were tested:
rAAV2-GFP alone, and bi-cistronic rAAV2 vectors encoding
either brain-derived neurotrophic factor (rAAV2-BDNF-GFP), a
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GFP), or a non-secreted protein growth-associated protein 43
(rAAV2-GAP43-GFP). A saline-injected control group was also
included. BDNF, CNTF, and GAP-43 have all been shown to
influence adult RGC viability and axonal regeneration [23], and
the impact of each of these genes when encoded in rAAV vectors
has been documented previously in rat PN-ON graft studies [8,9].
Five to eight months after the initial surgery, regenerated RGCs
were identified by retrogradely labeling them with fluorogold (FG)
injected into the distal end of each PN graft. Living retinas were
subsequently removed, wholemounted, and regenerated FG
positive (
+) RGCs were intracellularly injected with Lucifer Yellow
(LY). Expression of GFP in all rAAV vectors permitted
identification of transduced, regenerated RGCs. GFP
+ and non-
transduced GFP negative (
2) RGCs that had regrown an axon into
the PN graft were filled. After immunoprocessing for LY, soma
size and dendritic morphology were analyzed and quantified using
Neurolucida software. We observed gene-specific changes in the
morphology of identified, regenerating adult RGCs after long-
term rAAV2 therapy, not only in transduced RGCs but also in
non-transduced RGC populations. Furthermore, some changes
appeared to be subtype specific, seen only in large, type RI-like
RGCs.
Results
Impact of transgenes on RGC morphology
FG
+ RGCs that had regenerated an axon to the distal end of PN
grafts were identified and photographed under UV light (Fig. 1A,
G) and also at 488 nm to determine whether the RGCs were
transduced (GFP
+) or non-transduced (GFP
2; Fig. 1B, K, L). In all
groups, transduced RGCs were most frequently seen in temporal
retina, in the vicinity of the initial rAAV2 vitreal injection (Fig. 1D)
[14,24]. RGCs were injected iontophoretically with LY and a
photograph taken under 488 nm (Fig. 1C, I, M) for subsequent
identification of individual RGCs from immunolabelled and
Neurolucida traces (Fig. 1E, F, J, N). This procedure was repeated
on 20–50 RGCs per retina (Fig. 1D). The number of regenerated
FG
+ RGCs that were analyzed in each control or vector group is
shown in Table 1. For clarity, throughout the text for each of the 4
vectors used in this study we will denote transduced and non-
transduced (nt) FG
+ RGCs as GFP/ntGFP, BDNF/ntBDNF,
CNTF/ntCNTF or GAP43/ntGAP43 respectively.
In some vector groups, a significant proportion of the 375 fully
analyzed RGCs possessed one or more highly abnormal dendritic
morphologies, including either very sparse dendrites or unusually
tangled processes (Fig. 2A). The proportion of RGCs with such
abnormal dendritic morphologies was, compared to saline, not
significantly different in rAAV2-GFP and rAAV-GAP43-GFP
groups, but was significantly increased in the rAAV2-BDNF-GFP
and rAAV2-CNTF-GFP injected groups (X2=130; p,0.0001;
Fig. 2B).
Discriminant analysis (summarized in Table 2)
To quantify the morphological changes in regenerate RGCs
induced by transgene expression, we applied multivariate statistical
analysis to take into account all of the 15 parameters that were
measured using Neurolucida (see Materials and Methods for further
detail). We used discriminant analysis, a statistical technique used
for differentiating groups using multiple quantitative variables [25].
The analysis extracts canonical scores, which represent a transfor-
mation of the original measurements into an expression of maximal
differences between groups. Where significant differences were
detected between the canonical scores of experimental and control
groups, we then performed post-hoc analysis of the morphological
measurements to determine the nature of these differences.
Discriminant analysis of the 5 treatment groups confirmed
significant differences between all treatment groups. Most of the
differences relative to control groups (saline and rAAV2-GFP
injected retinae) were contained in canonical scores 1 and 2
(Fig. 3A). In addition, canonical score 3 demonstrated that RGCs
from rAAV2-GFP transduced retinae differed from saline injected
controls (p,0.0001; Fig. 3B). Because the canonical scores
represent a transformation of the data from the morphological
parameters they cannot be attributed to specific morphological
differences. We therefore performed ANOVA and posthoc
analysis on all of the measurements to identify how GFP
expression affected morphology. However, no individual param-
eter was found to be responsible for this difference either in
transduced or non-transduced cells, suggesting the effects of GFP
on RGC morphology were relatively minor. Nonetheless in all of
the following analyses we compared treatment groups to rAAV2-
GFP controls and not to saline injected controls.
In rAAV2-BDNF-GFP injected retinae, the soma size of all LY-
injected, regenerating RGCs was significantly increased compared
to LY labeled, FG
+ RGCs in rAAV2-GFP controls (P,0.0001;
Fig. 3C). In addition, dendrites were longer (p=0.02), field size
was larger (p=0.003; Fig. 3D), and total and mean nodal distances
were longer (p=0.008 and p=0.003 respectively). When
transduced and non-transduced RGCs were analyzed separately,
most of the changes could be attributed to transduced BDNF
neurons, which had larger somata (P,0.0001) and larger field size
(p=0.03) compared to their GFP transduced counterparts. No
significant differences were observed in regenerate ntBDNF
compared to ntGFP RGCs.
In rAAV2-CNTF-GFP injected retinae, the only difference
compared to rAAV-GFP injected retinae was a significant increase
in the soma size of RGCs (p,0.0001). The increase was observed
in both CNTF and ntCNTF RGCs compared to GFP (p,0.0001)
and ntGFP (p=0.0014) RGCs respectively. In addition, CNTF
RGCs had significantly larger soma size compared to ntCNTF
RGCs (Table 2; p=0.0085).
For RGCs in rAAV2-GAP43-GFP injected retinae, the fractal
count [26] was significantly increased compared to rAAV2-GFP
controls (p=0.02), and dendrite density was also increased
(p=0.02). Analysis of transduced versus non-transduced neurons
revealed that the difference in fractal count was found only in
transduced GAP43 RGCs (p=0.04), whereas an increase in
dendritic density was found only in ntGAP43 RGCs (p=0.03).
Sholl analysis
To further characterize the morphological changes induced in
RGCs by the different transgenes, we also performed a Sholl
analysis, the most commonly used method to measure dendritic
field density and structure [27]. The method assesses the
distribution of dendrites as a function of eccentricity using the
cell body as the centre. Analysis of the total cell population
revealed that RGCs in rAAV2-BDNF-GFP and rAAV2-CNTF-
GFP injected retinae had significantly denser dendrites from
200 mm to 400 mm (BDNF) and from 320 mm to 400 mm (CNTF)
distal from the cell body compared to rAAV2-GFP controls
(Fig. 3E). No significant differences were detected when trans-
duced and non-transduced RGCs were analyzed separately.
Assessment of morphological changes in one putative
RGC subtype
The analysis above demonstrates that each transgene had a
distinct and significant impact on dendritic morphology of RGCs.
Gene Therapy Alters Neuronal Morphology
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subtypes of RGCs within the rat retina with characteristic
morphologies [28,29]. It is therefore desirable to analyze these
subtypes separately to confirm that morphological differences
between subtypes have not masked differences due to transgene
expression. However, unlike in mouse, in which there is a
correspondence of specific molecular markers with RGC cell
subtype [30,31], in rat there is no definitive method of classifying
all RGC subtypes independent of morphology. The only
phenotypic marker consistently used in rat RGCs is melanopsin,
which is expressed in about 3% of RGCs. However, in the specific
context of RGC axonal regeneration into a PN-ON graft, murine
melanopsin expressing RGCs do not regenerate more frequently
than other RGCs [32], thus in our rat study we would expect only
about 10–15 regenerate RGCs to be melanopsin positive, clearly
too few for any justifiable analysis.
Nonetheless, there is consensus across many studies that rat
RGCs can be effectively classified into three or four main subtypes
based on cell body size, number of dendrites, dendritic field size
and stratification [29,33–36]. Most importantly, this morpholog-
ical classification has also been applied to RGCs in peripheral
nerve grafted animals [37,38], suggesting that regenerating RGCs
Figure 1. Injection, tracing and identification of individual RGCs from rAAV2-injected retinae. Photomicrographs and Neurolucida-
traced images showing the procedure for labeling and identifying regenerating retinal ganglion cells (RGCs). Regenerating RGCs were first identified
based on retrograde labeling (Fluorogold; A), and transduced cells were based on GFP expression (GFP
+ RGC is shown in B). After filling the dendrites
with Lucifer yellow (C), the RGC was again photographed. This procedure was repeated on 20–50 RGCs per retina (D). The visualization of dendritic
architecture was further enhanced with Lucifer yellow immunohistochemistry, and individual cells with complete fills (E) were traced using
Neurolucida software. The Neurolucida trace (F) was compared to images of the cells taken immediately after the Lucifer yellow injection (C) to allow
each cell to be classified as transduced (GFP
+) or as a non-transduced ‘‘bystander’’ neuron (GFP
2). G–N: Representative images of RGCs that were
retrogradely labeled with Fluorogold (G, K), identified as GFP
2 (H) or GFP
+ (L), injected with Lucifer yellow (I,M) and traced using Neurolucida software
(J,N). Scale bars: 100 mm.
doi:10.1371/journal.pone.0031061.g001
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induced alterations in dendritic architecture [39]. Consistent with
this, the outcome of our whole population analysis of the 375 LY-
labeled RGCs did not reveal any overall change in the number of
primary dendrites emanating from RGCs in any vector group.
Using only morphological criteria, the best consensus across all
studies is the identification of the RGC 1 subtype, known as RI in
regenerating RGCs [37,38]. These cells have a large soma, 4–6
primary dendrites and large dendritic field area with a very typical
dendritic branching pattern [29,36]. These same criteria identify
type RI RGCs following a PN graft [37,38]. Types 2 and 3 have
smaller cell bodies than type 1 cells, fewer than 3 primary
dendrites, and are differentiated primarily by the number of
branch points but this measure becomes unreliable in regenerating
RGCs in which branching density is greatly reduced [37].
Taking this previous literature into account, we conservatively
assessed whether it was possible to identify RI-like RGCs within
our general population using the number of primary dendrites, cell
body size and typical dendritic branching pattern as the essential
criteria. We identified all RGCs that had large somas, more than 4
primary dendrites and a ‘‘typical’’ type RI dendritic branching
pattern (examples are shown in Fig. 4A). All RGCs from each
treatment group were then plotted on separate scatterplots with
the number of dendrites on the X axis and cell body size on the Y
axis. RGCs that were identified as ‘‘RI-like cells’’ are shown as
grey circles to identify them relative to the other cells (white
diamonds; Fig. 4B). RI-like cells clustered together to the upper
right of the scatterplot for all treatments, suggesting that they
formed a coherent group. Most importantly, even though BDNF
and CNTF RGCs had consistently larger cell bodies than the
other treatment groups, the clustering was still apparent. To
further confirm that our identification was robust, we performed a
discriminant analysis on all RGCs, where cells were either
classified as ‘‘RI’’ or ‘‘other’’, and these cells were found to cluster
into two distinct groups, regardless of treatment (Fig. 4C).
Analysis of RI-like RGCs
Plots showing canonical scores 1 (X axis) and 2 (Y axis) from
multivariate discriminant analysis of dendritic morphology for
transduced and non-transduced RI-like RGCs in each vector
group are shown in Figure 5A; the data are summarized in
Table 2. As seen in Figure 5B, BDNF and ntBDNF RI-like RGCs
possessed soma areas that were significantly increased compared to
GFP and ntGFP cells respectively (p=0.04 for both). In ntBDNF
RGCs, there was also a strong trend for a larger dendritic field
area compared to ntGFP cells (p=0.06; Fig. 5B). In addition,
transduced and non-transduced RGCs in rAAV2-BDNF-GFP
injected eyes were significantly different from each other, ntBDNF
RGCs having a larger dendritic field area compared to BDNF
RGCs.
In CNTF and ntCNTF RI-like RGCs, soma area was also
significantly increased compared to GFP and ntGFP cells
respectively (Fig. 5B). In addition, dendrites of ntCNTF RGCs
were less complex than those of ntGFP cells, with fewer nodes and
reduced branch order, as well as increased total and mean
terminal/nodal distances, suggesting growth of terminal segments.
As observed in rAAV2-BDNF-GFP injected eyes, transduced and
non-transduced RGCs in rAAV2-CNTF-GFP injected eyes were
significantly different; compared to CNTF RGCs, ntCNTF RGCs
had significantly fewer nodes and lower order branching,
confirming the loss of complexity in these non-transduced, or
bystander, neurons.
Morphological differences in RI-like RGCs from rAAV2-
GAP43-GFP injected eyes were attributed to an increase in
tortuosity in GAP43 transduced cells compared with GFP
transduced controls (Fig. 5B). Note here that Sholl analysis of
RI-like RGCs failed to reveal any significant differences (data not
shown).
Stratification of dendritic tree
For the majority of FG
+ RGCs, the dendritic tree extended
within the inner half of the inner plexiform layer (on average
within 30 mm of the cell body) suggesting that they were ON
centre cells [40]. A small number of cells appeared to be either
OFF or bistratified (ON/OFF) cells but these were not analyzed
statistically due to low numbers (0–3 cells per treatment group).
Within the population of presumed ON cells, sampled across a
similar range of retinal eccentricities, the depth profile of dendritic
trees was increased in all treatment groups, and this was mainly
due to branches extending to an abnormal depth within the IPL
(BDNF: p=0.004; CNTF: p=0.003; GAP43: p=0.01; all
compared to GFP controls Fig. 6A–C). BDNF affected only
transduced RGCs (p=0.049), CNTF affected both transduced
and non-transduced neurons (p=0.02 for both), and GAP43
affected only transduced RGCs (p=0.002) compared to appro-
priate transduced or non-transduced GFP controls. In the
population of RI-like cells, RGCs in rAAV2-BDNF-GFP injected
eyes were not affected, whereas dendrites of rAAV2-CNTF-GFP
transduced and non-transduced, and rAAV2-GAP43-GFP trans-
duced RGCs ramified more deeply (p=0.02; p=0.03; p=0.0009
compared to appropriate transduced or non-transduced GFP
controls). In RGCs with grossly abnormal dendritic morphology,
while dendritic branches were occasionally seen at the border of
the inner plexiform and inner nuclear layers (INL), these processes
were not seen to penetrate the INL itself (Fig. 6D, E).
Discussion
The potential clinical benefits of using gene therapy to deliver
growth factors to treat neurological or retinal dysfunction are
Table 1. Number of RGCs analyzed in each control and
experimental group for all RGCs, and for those identified as
Type RI cells.
All cells Type RI
Saline 68 17
BDNF 73 40
ntBDNF 14 7
BDNF 59 33
CNTF 117 42
ntCNTF 62 22
CNTF 55 20
GAP43 63 19
ntGAP43 16 4
GAP43 47 15
GFP 54 20
ntGFP 14 5
GFP 39 15
Total analysed 375 138
No axon/FG- 66
Incomplete fill 59
Grand Total 500
doi:10.1371/journal.pone.0031061.t001
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compared to appropriate GFP transduced or non-transduced control groups.
ALL RGCS ALL RGCS TYPE I-LIKE RGCS
BDNF I n c r e a se dso m aa r e a( P,0.0001),longerdendrites
(p=0.02), largerdendritic field (p=0.003),increased total
and averagenodal distance(p=0.008;p=0.03).Sholl
analysis:denserdendrites.Deeper stratification
(p=0.004).Increased prevalence ofaberrant morphology.
BDNF
transduced
Increased soma area (p,0.0001),
increased field size (p=0.003),
deeper stratification (p=0.049).
Increased soma area (p=0.04)
BDNF non-
transduced
No change Increased soma area (p=0.04), increased field area
(trend: p=0.063), deeper stratification (p=0.01).
CNTF Increased soma area (p,0.0001). Sholl analysis:
denser dendrites. Deeper stratification (p=0.003).
Increased prevalence of aberrant morphology.
CNTF
transduced
Increased soma area (p,0.0001),
deeper stratification (p=0.02).
Increased soma area (p=0.0002),
deeper stratification (p=0.02).
CNTF non-
transduced
Increased soma area (p,0.0014),
deeper stratification p=0.02
Increased soma area (p=0.001), reduced complexity
(nodes (p=0.006), branch order (p=0.03), increased
terminal/nodal distance (total and mean: p=0.05),
deeper stratification (p=0.03).
GAP43 Increased complexity (fractal count: p=0.02).
Increased dendritic density (p=0.02). Deeper
stratification p=0.01
GAP43
transduced
Increased complexity (fractal
count: p=0.04). Deeper
stratification (p=0.002).
Increased tortuosity (p=0.01).
Deeper stratification (p=0.0009)
GAP43 non-
transduced
Increased dendritic density
(p=0.03)
No change
doi:10.1371/journal.pone.0031061.t002
Figure 2. Increased prevalence of RGCs with abnormal morphology in retinae injected with rAAV2-BDNF-GFP and rAAV2-CNTF-
GFP. A: Representative Neurolucida traces showing retinal ganglion cells (RGCs) with abnormal morphology. The term ‘aberrant morphology’ was
used to describe RGCs with one extremely long dendrite that was exceptionally tortuous or abnormally sparse or asymmetric. Arrows indicate axons.
The rAAV2 treatment group is indicated under each cell; nt=non-transduced RGC. B: Pie charts showing frequency distribution of RGCs with aberrant
morphology in control and experimental groups.
doi:10.1371/journal.pone.0031061.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31061Figure 3. Evidence for morphological differences in RGCs from retinae injected with rAAV2 encoding different transgenes. A: Plot
showing canonical scores 1 (Y axis) and 2 (X axis) from a multivariate discriminant analysis of dendritic morphology of all retinal ganglion cells (RGCs).
Plots show the first two canonical scores that together represent more than 80% of the variance. Axes represent units of standard deviation. Circles
represent the 95% confidence region to contain the true mean of the treatment groups. Black lines show the coordinate direction (i.e. morphological
parameters measured in Neurolucida) in canonical space. Note that the length of the lines is not representative of effect size due to the
multidimensional nature of the analysis. B–D: Box plots showing median and quartiles for selected morphological parameters that were significantly
different between treatment groups. B: values for the third canonical score which accounts for the significant difference between Saline and rAAV2-
GFP injected groups. Means for soma area (C) and dendritic field area (D) are shown for all treatment groups. * p,0.05; **p,0.001; *** P,0.0001. E:
Sholl analysis of all RGCs by treatment group. Error bars=standard error of the mean. Asterisk (*) indicates significant (p,0.05) difference between
rAAV2-BDNF-GFP and GFP; # indicates significant (p,0.05) difference between rAAV2-CNTF-GFP and GFP.
doi:10.1371/journal.pone.0031061.g003
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of appropriate viral vectors may also be an effective treatment after
neurotrauma [14]. Depending on circumstances, such therapies
may need to be long term and it therefore seems prudent to
examine whether there are any unintended consequences of
sustained delivery of such factors on neuronal structure and
function. We have shown previously that intraocular injection of
rAAV-BDNF-GFP or rAAV-CNTF-GFP influences adult RGC
survival and regeneration after injury [8,9]. Here we show that, in
FG
+ RGCs that had regrown an axon into PN grafts and therefore
had comparable access to factors expressed by the grafted PN
tissue, intravitreal delivery of vectors encoding BDNF, CNTF or
GAP43 nonetheless resulted in significant and complex changes in
the dendritic morphology of the total population of regenerate
neurons.
Each factor induced specific structural changes but overall,
BDNF and CNTF increased RGC soma size, while BDNF
increased dendritic field size and CNTF and GAP43 altered
dendritic complexity. These changes did not obviously restore
regenerating RGCs towards a more ‘‘normal’’ morphology, but
rather added to the effects that were induced post-injury; thus
BDNF further increased dendritic field size and CNTF reduced
complexity in RGCs whose dendritic arbors had become larger
[46] and less complex [37] following optic nerve lesion and PN
transplantation. Furthermore, all three transgenes induced abnor-
mal dendrite growth that was not restricted to normal sub-laminae
within the IPL. A significant finding was that the morphologies of
non-transduced (GFP
2), FG
+ RGCs in rAAV injected eyes were
also differentially affected, thus the total impact of a given
transgene is multifarious and extends to bystander neuronal
populations [47].
As described in the Results, others have argued that it is possible
to recognize and classify at least some rat adult RGC subtypes that
are regenerating an axon into a PN graft [37,38]. Regenerating
type RI RGCs in particular appear to display the most
characteristic and convincing similarities to this same class in
normal retina. We identified all RGCs that had large somas, more
than 4 primary dendrites and a ‘‘typical’’ type RI dendritic
branching pattern and discriminant analysis showed that these
cells were always clustered in a separate group, irrespective of
vector treatment. The impact of rAAV-CNTF-GFP injections was
most obvious in these RGCs, with a significant reduction in the
complexity of the dendritic arbors. While additional phenotypic
markers for RGC subtypes, other than morphology, would have
been helpful in these experimental animals, few such markers are
available for rat RGCs. Importantly, characterization of regener-
ating, type 1-like RGCs has been reported in other species [48–50]
and in the cat a number of physiological studies on RGCs
regenerating axons into PN grafts unequivocally confirms the
phenotype of morphologically characterized alpha cells as being
Y-type in character although with some altered receptive field
properties [51,52].
Growth factors and dendritic morphology
BDNF. Studies of nervous system development and
regeneration reveal pleiotropic effects of growth factors on
dendritic morphology [17,19,39,53,54]. It is generally accepted
that BDNF increases dendritic field size and complexity of
branching [55,56], although BDNF may also cause a loss of
dendrite complexity [57,58]. Consistent with these complex
effects, we found that RGCs were differentially affected
depending on whether RGCs were transduced or non-
transduced. Dendritic field area was consistently increased in
RGC within rAAV2-BDNF-GFP injected eyes, and was
accompanied by increased dendritic length, specifically due to
longer nodal segments, suggesting interstitial growth [46]. Perhaps
surprisingly, the increased growth was not accompanied by
changes in branch density, perhaps due to altered dynamics of
loss and formation of dendritic branches; in Xenopus tadpoles,
target-derived (tectal) BDNF increases, whereas local (retinal)
BDNF decreases, RGC dendrite complexity [58]. The different
effect of BDNF depending on whether it is local or target-derived
is relevant because in the present study the adult RGCs
regenerated into blind-ended PN grafts and thus were exposed
to factors expressed in the grafts but they could not re-connect
with central targets. The resulting loss of balance between retinal
and target BDNF may have contributed to the non-characteristic
growth patterns we observed.
A key finding was the effect of rAAV2-BDNF-GFP injections on
both transduced and non-transduced, regenerating RI-like RGCs.
Interestingly, the effects were most pronounced in the non-
transduced, bystander population. BDNF secreted from single cells
within brain slices of immature cortex has been shown to act as an
‘‘intercellular morphogen’’, increasing dendritic growth in neigh-
bouring neurons [16,59]. There are many possible mechanisms
whereby secreted, transgene-derived BDNF might exert its effects
on RGCs: BDNF effects can be mediated by full-length (TrkB-FL)
and truncated (TrkB-T1) receptors, and by the p75 receptor.
TrkB-FL promotes dendritic growth and complexity via recruit-
ment of PI3-kinase and perhaps MAP kinase signaling pathways
[17,56] although in our model TrkB-FL signalling may be less
relevant because the receptor may have been down-regulated in
response to sustained high levels of BDNF [60]. TrkB-T1 has
slightly different effects than TrkB-Fl in that it increases dendrite
growth in regions distal to the soma and inhibits proximal
branching, at least in cortical pyramidal neurons [61]. In addition,
BDNF signalling via p75 may also be involved because in
hippocampal neurons, p75 overexpression reduces dendrite
complexity [57] and NGF activation of p75 increases dendrite
length [62].
CNTF. Sustained expression of CNTF in regenerating RGCs
was associated with increased cell body size in all RGCs, but
increased aberrant dendritic growth and a loss of dendritic
complexity were detectable only in RI-like cells. Interestingly,
changes in dendritic architecture were most pronounced in non-
transduced RGC populations. Intravitreal delivery of rAAV2-
CNTF-GFP results in extensive elongation of RGC axons [8,9]
Figure 4. Classification of RI-like RGCs. A: Neurolucida traces of representative RI-like retinal ganglion cells (RGCs) from control and experimental
rAAV2 groups. Transduced and non-transduced (nt) FG
+ RGCs in the 4 rAAV2 groups are labeled as GFP/ntGFP, CNTF/ntCNTF, BDNF/ntBDNF or
GAP43/ntGAP43 respectively. B: Clustering of transduced and ntRI-like RGCs based on the number of primary dendrites (X-axis) and soma area (Y axis)
in control and experimental groups. RI-like RGCs are denoted by grey circles and remaining cells by white diamonds. C: Plot showing canonical scores
1 (X axis) and 2 (Y axis) from a multivariate discriminant analysis of dendritic morphology of RI-like RGCs and ‘‘other’’ RGCs. Plots show the first two
canonical scores that together represent more than 80% of the variance. Axes represent units of standard deviation. Solid black circles represent the
95% confidence region to contain the true mean of the group. Black lines show the coordinate direction (i.e. morphological parameters measured in
Neurolucida) in canonical space. Note that the length of the lines is not representative of effect size due to the multidimensional nature of the
analysis.
doi:10.1371/journal.pone.0031061.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31061Figure 5. Evidence for morphological differences in type RI-like RGCs from retinae injected with rAAV2 encoding different
transgenes. A: Plots showing canonical scores 1 (X axis) and 2 (Y axis) from multivariate discriminant analysis of dendritic morphology for RI-like
retinal ganglion cells (RGCs). Plots show the first two canonical scores that together represent more than 80% of the variance. Axes represent units of
standard deviation. Circles represent the 95% confidence region to contain the true mean of the group. Black lines show the coordinate direction (i.e.
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dendritic architecture, although CNTF and leukemia inhibitory
factor (LIF) have been reported to induce dendritic retraction in
cultured sympathetic neurons [15]. The actions of CNTF, LIF and
other cytokines are regulated by suppressor of cytokine signaling
(SOCS) molecules and SOCS3 deletion enhances RGC axonal
regeneration [63]. We previously reported that intravitreal CNTF
injection results in a long lasting increase in SOCS3 expression in
RGCs [64]. The more pronounced effects of rAAV2 mediated
expression of the secretable form of CNTF on the dendritic
morphology of non-transduced RGCs may reflect lower levels of
SOCS expression in these bystander cells compared to transduced
RGCs, the latter therefore having a reduced capacity to respond to
the cytokine [24].
GAP43. AAV-GAP43-GFP expression primarily affected
dendritic complexity and branching, and is consistent with the
influence of GAP43 on cytoskeletal structure and neurite/axonal
growth [65–67]. There is also direct evidence that motifs found in
the GAP43 protein regulate dendritic growth and branching in
cultured hippocampal cells [68]. We observed significant changes
in all RGCs, characterized by the development of denser and
more complex dendritic trees with more tortuous dendrites. It is
unclear how vector induced GAP43 protein expression affected
field density of non-transduced RGCs, given that the protein is
not normally secreted. However, GAP43 may promote secretion
of other factors that alter the growth of neighboring neurons.
One candidate is the protease nexin 1 (PN-1), a serine-protease
and thrombin inhibitor expressed in glia and neurons in vivo
[69,70]. Secreted PN-1 alters extracellular protease activity,
influencing neuronal development [71] including neurite
outgrowth [72–75]. GAP43 may influence PN1 secretion [76],
potentially altering the retinal environment and contributing to
the dendritic changes described here. Note that PN1 has also
been implicated in pathological situations [70] and in Alzheimer’s
disease [77] where abnormal dendritic morphologies are
common.
Abnormal morphologies and stratification
Previous studies of RGC dendritic morphology following ON
lesions with or without a PN graft have described a high
proportion of ‘‘unclassifiable’’ cells [37]. Abnormal morphologies
were most frequent in rAAV2-CNTF-GFP and rAAV2-BDNF-
GFP injected retinae, suggesting that these two transgenes
promote aberrant arborization and growth beyond what is
normally observed following ON crush or PN transplantation
[46,51,78].
Subsets of lamina-specified RGCs are tuned to distinct visual
features [40,79] and disruption to stratification leads to compro-
mised visual function. As in the cat [52,80,81], the majority of
regenerate RGCs possessed dendrites characteristic of ON-
responsive cells, however we commonly observed inappropriate
extension of dendritic branches into deeper regions of the IPL.
Abnormal stratification was seen more frequently in rAAV2-
CNTF-GFP and rAAV2-GAP43-GFP injected eyes and resem-
bled the dendritic trees in retinae after exposure to increased
glutamate levels [82,83].
Conclusions
While vector-mediated expression of secreted growth factors in
neurons and other cells undoubtedly has beneficial effects on cell
viability and regenerative growth, we now show that long-term
overexpression of such transgenes alters the dendritic morphology
of both transduced and non-transduced regenerating neurons,
potentially altering the pattern and efficacy of the afferent synaptic
input to these cells [84]. To determine whether similar transgene-
induced changes are seen in normal RGCs we are currently
completing a separate quantitative study examining changes in
dendritic architecture of uninjured RGCs. Altered dendritic
morphologies may affect the function of any conserved or
reconstructed neural circuits, raising important questions for
future study. In the visual system such changes may be a benefit
or a hindrance to behavior; changes in dendritic field size and/or
complexity in different RGC classes may increase detection
capabilities in retinae with reduced RGC numbers but may also
negatively impact upon visual acuity [52]. Altered dendritic
architecture in other CNS regions would obviously be associated
with different functional processing issues. While the time-course
of the observed dendritic changes and how they relate to axonal
regeneration remains to be determined, the present data suggest it
is prudent to develop reliable systems that allow the effective
regulation of transgenes, especially if gene therapy is to be used to
provide neurotrophic support during the treatment and clinical
management of neurodegeneration and neurotrauma.
Materials and Methods
Data were obtained from female Wistar rats aged 8–10 weeks at
the time of rAAV2 injection and PN-ON surgery. Rats were
purchased from the Animal Resources Centre (WA) Experimental
work was approved by The University of Western Australia
Animal Ethics Committee and conformed to national NHMRC
guidelines.
AAV vectors
Each vector was commercially produced by GTC Virus Vector
Core (NC, USA) and was generated from either the pTRUF12
plasmid (GFP, BDNF and GAP43) or the pTRUF12.1 plasmid
(CNTF; gift of Prof. Joost Verhaagen). For bi-cistronic rAAV2
vectors the relevant gene sequence also contained a post IRES site
that also permitted subsequent GFP expression, hence resulting in
the production of two individual proteins (the growth factor
protein and the GFP protein as a marker for transduction).
Expression was driven by the cytomegalovirus early enhancer
chick-b-actin (CMV-CAG) promoter. The CNTF gene sequence
included a nerve growth factor signal to allow secretion of the
vector produced CNTF protein (gift of Prof. Sendtner). Due to the
rAAV2 packaging size limitation this vector was based on the
pTRUF 12.1 plasmid with a CMV-CAG promoter that lacked a
promoter intron and thus provided sufficient space for the
transgene [8]. Previous in vitro and in vivo studies using the
CNTF, BDNF and GAP-43 rAAV-2 constructs have shown by
Western blot, ELISA and immunohistochemistry that transduced
cells express biologically active proteins and promote RGC
survival and axonal regeneration [2,8,9,85].
morphological parameters measured in Neurolucida) in canonical space. Note that the length of the lines is not representative of effect size due to
the multidimensional nature of the analysis. B: Box plots showing median and quartiles for selected morphological parameters that were significantly
different between treatment groups. Transduced and non-transduced (nt) FG
+ RGCs in the 4 rAAV2 groups are labelled as GFP/ntGFP, CNTF/ntCNTF,
BDNF/ntBDNF or GAP43/ntGAP43 respectively. Asterisk (*) indicates groups that are significantly different from ntGFP RGCs (p,0.05) and # indicates
groups that are significantly different from GFP RGCs (p,0.05).
doi:10.1371/journal.pone.0031061.g005
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Rats were anaesthetized with an intraperitoneal (ip) injection of
a 1:1 mixture of ketamine (100 mg/ml) and xylazine (20 mg/ml;
1 ml/kg). For vitreal injections, 4 ml of either saline, rAAV2-GFP,
rAAV2-BDNF-GFP, rAAV2-CNTF-GFP or rAAV2-GAP43-GFP
(n=5 per group) was injected into the temporal part of the left eye
via a glass micropipette inserted just behind the ora serrata, the
pipette tip angled in order to avoid damage to the lens. All vector
concentrations were 1610
12 genome copies/ml. Seven to nine
days later, rats were again anaesthetized (see above) and the ON
was cut about 1.5 mm behind the eye and a segment of PN was
grafted onto the stump to enhance regeneration [22,23]. The graft
consisted of a 1.5 cm segment of autologous tibial nerve sutured
onto the proximal stump of the cut ON with 10/0 suture (Ethilon;
Johnson & Johnson, Australia). The distal portion of the PN was
positioned over the skull and the end sutured to connective tissue
using 6/0 suture. Care was taken to avoid damaging orbital blood
vessels and the ophthalmic artery lying beneath the ON; vascular
Figure 6. Abnormal stratification in RGCs from retinae injected with rAAV2 encoding different transgenes. A–C: Side views of
Neurolucida traces showing examples of abnormal stratification in each rAAV2 treatment group. Arrows indicate axons and ‘‘s’’ is immediately below
the soma. The scale bar in A applies to the three traces. D: Neurolucida trace of an rAAV2-GAP43-GFP transduced retinal ganglion cell (RGC). Ai and Aii
are side views. E: confocal image of the same cell as in D; pink is Cy3 immunofluorescence for lucifer yellow, wholemount counterstained with
Hoechst 33342 (blue). Areas a and b are shown in more detail. Area a is shown in panels ai-aiv. Panel ai shows a higher power magnification of a and
panels aii and aiii show the XZ and YZ projections respectively at the crosshairs shown on panel ai. Panel aiv shows the full YZ projection of panel a
and shows that dendritic processes descend through the inner plexiform layer and run along the border of the inner nuclear layer (INL), but they do
not enter the INL. Area b is shown in panel bi as an XZ projection showing the relationship of this dendritic branch to the INL. GCL, ganglion cell layer.
Scale bar in ai: 25 mm.
doi:10.1371/journal.pone.0031061.g006
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confirmed in each rat. Animals received a subcutaneous injection
of buprenorphine (0.02 mg/kg, Temgesic; Reckitt & Colman,
UK) and an intramuscular injection of Benacillin (0.1 ml, Troy
Laboratories Pty. Ltd. Australia).
Retinal wholemount preparation
Grafted animals survived for 5–8 months before further
analysis. The range of post-graft survival resulted from the fact
that it was only possible to process a small number of animals at
any given time. Intracellular RGC injections were done on 16
different days during that period. To control for any effect of post-
operative survival time on RGC morphology, rats from different
AAV groups were sampled across the 5–8 month range, 80% of
animals sampled between 6 and 8 months after surgery. For
example, PN grafted rats injected with rAAV2-CNTF-GFP (n=5)
were injected on weeks 26, 27, 30 (2 animals) or 33 after surgery
while rAAV2-BDNF-GFP rats (n=5) were injected on weeks 25,
26, 31, 32 or 33. Two to three days prior to sacrifice, rats were
anaesthetized as above and RGCs were retrogradely labeled with
4% FG (0.5 ml) injected into the distal end of the PN graft, more
than 1 cm beyond the suture point with the transected ON. Rats
were sacrificed with pentobarbitone (150 mg/kg, ip) and the whole
retina was rapidly removed from the eyecup in oxygenated AMES
buffer and flat mounted RGC-side facing down onto a glass slide.
A circle of black Millipore filter paper was lowered onto the retina.
The tissue adhered to the filter paper and was turned over and
placed RGC-side up in oxygenated AMES buffer.
Single cell injections
The retina was placed in a slide chamber, immobilized with a
small weight and superfused with oxygenated AMES for the
duration of the experiment. Glass micropipettes (resistance: 50–
300 MV) were filled by capillary action with LY (Molecular
Probes/Invitrogen; 2% in 0.1 M Tris buffer). RGCs were injected
with LY by inserting the micropipette into the cell soma under the
control of a micromanipulator. Injections lasted for 2–5 min until
dendrites appeared completely filled. The micropipette was slowly
removed and the filled RGCs visualized and photographed under
UV light and also at 488 nm to determine whether regenerate
FG
+ RGCs were transduced (GFP
+) or non-transduced (GFP
2)b y
the respective rAAV vectors (Fig. 1). We note that post-IRES GFP
expression in AAV vectors can be lower compared to GFP driven
directly by a promoter [86], thus it is possible that some apparently
GFP
2 RGCs were transduced but the GFP was not discernable.
However, based on GFP expression we previously determined the
transduction efficiency of our bi-cistronic vectors in normal rat
RGCs and found little difference between these vectors and AAV-
GFP [8]. Furthermore, the present quantitative analysis consis-
tently revealed significant differences between transduced and
non-transduced RGC populations, thus we argue that if any
RGCs were incorrectly characterized as non-transduced, their
number was very small. Between 20–50 RGCs were intracellularly
injected per retina (Fig. 1D). In all groups, RGCs were most easily
visualized and injected at mid-retinal eccentricities (Fig. 1D), thus
there was only minimal sampling from central or peripheral retina.
Immunohistochemistry
At the end of each experiment, the retina was removed from the
slide chamber, gently peeled off the filter paper and fixed in 4%
paraformaldehyde for 2 hrs at room temperature in the dark. The
fixed retinae were washed in PBS for 3610 min and incubated
overnight at 4uC with an anti-LY antibody (Santa Cruz
Biotechnology), 1:500 dilution in 1% triton-X-100, 1% BSA in
PBS. Following a one hour wash in PBS at room temperature,
retinae were incubated with a Cy3 goat-anti-rabbit antibody
(Jackson Laboratories), 1:300 in 1% triton, 1% BSA in PBS, for
4.5 hrs at room temperature in the dark. Retinas were then
washed 3 times for 10 min in PBS and mounted in Citifluor,
coverslipped and sealed with nail varnish. Slides were stored at
4uC until further analysis.
Quantitative and statistical analysis of retinal ganglion
cell morphology
RGCs were manually traced directly from immunolabelled
retinal wholemounts using Neurolucida software and analyzed in
Neurolucida explorer. The experimenter was blinded to treatment
group. In all groups, RGCs were sampled from a similar range of
eccentricities. Use of a digitized stage allowed 3-dimensional
measurements to be taken directly from the tissue without confocal
imaging. The resulting Neurolucida traces contained quantitative
data in the Z-axis allowing an estimation of dendritic stratification
depth. In selected RGCs with abnormal dendritic trees, stratifi-
cation relative to the inner nuclear layer was visualized by
counterstaining wholemounts with Hoechst 33342 (Sigma) dye.
Dendrites were traced at 406magnification under oil immersion
(Uplan Apo 406/1.00 oil Iris).
Due to various technical problems it was not possible to process
retinae from 4 of the 25 PN-ON grafted eyes. In the remaining 21
retinae (4 saline, 4 rAAV2-GFP, 4 rAAV2-BDNF-GFP, 5 rAAV2-
CNTF-GFP and 4 rAAV2-GAP43-GFP) a total of 500 cells in the
ganglion cell layer were injected and their dendrites manually
traced using Neurolucida. Of these, 125 (25%) were discarded,
either because (i) after fixation and processing some were found
not to be FG
+ or did not have a clearly labeled axon projecting to
the optic disk and therefore may not have been RGCs, (66 cells),
or (ii) because the dendrites were extremely abnormal in
appearance and it was not possible to be certain whether this
was due to incomplete LY fills or genuine morphological changes
(59 cells).
Analysis of morphology
As previously described [37], we observed RGCs with
morphologies comparable to those of normal intact cells [29], as
well as RGCs with one or more abnormal structures including
either very sparse dendrites or unusually tangled processes. To
determine whether different transgenes were more likely to induce
these abnormal morphologies, we compared the proportion of
cells in each treatment group with abnormal dendrites using a Chi
squared test.
To further characterize differences between RGCs we per-
formed multivariate analysis (Discriminant analysis; JMP) of key
morphological RGC parameters [87]. Parameters measured for
each cell were: soma area, number of nodes, number of primary
dendrites, total dendrite length, dendritic field area, average
segment tortuosity, maximum order branching, fractal count,
dendritic density (dendritic field area/total dendritic length), total
terminal distance, average terminal distance, total nodal distance,
average nodal distance, total terminal/nodal distance and average
terminal/nodal distance.
A multivariate analysis was carried out to determine whether
RGC morphology was significantly different between treatment
groups. This analysis provided 4 canonical scores for each cell
which were analyzed by ANOVA and confirmed to be
significantly different between treatment groups (Tukey’s post
hoc test; p,0.0001 for all treatment groups for at least one of the
canonical scores). Measurements of morphological parameters (eg.
cell soma size, dendrite length etc) were then compared by
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identify which parameters were responsible for the differences.
To determine whether transgenes had differential impact on
transduced and non-transduced cells in each treatment group,
transduced cells in experimental retinae were compared to
transduced cells in rAAV2-GFP injected retinae and non-
transduced cells in experimental retinae were compared to non-
transduced cells in rAAV2-GFP injected retinae. Transduced and
non-transduced cells were also compared within treatment groups.
This analysis provided 3 canonical scores for each treatment, that
were analyzed by ANOVA and post hoc tests (Tukey). If post hoc
analysis of canonical scores revealed significant differences
between groups, measurements of morphological parameters were
then analyzed by ANOVA as described above.
Dendritic tree morphology was also assessed using Sholl analysis
[27], which involves counting the number of dendrites intersecting
concentric circles of increasing diameter (20 mm intervals)
centered on the cell body. The radial distribution of dendrites
was analyzed by ANOVA (repeated measures, Bonferroni post-
hoc test). All 375 Neurolucida traces are available on the public
data base NeuroMorpho.Org.
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